查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1705487

2025年全球核医放射性同位素市场报告

Nuclear Medicine Radioisotopes Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年核医放射性同位素的市场规模将强劲成长。预计到 2029 年将成长至 124 亿美元，复合年增长率为 8.5%。预测期内的增长可归因于医疗支出的增加、医疗基础设施的扩大、对环境永续性的认识的提高、教育宣传活动和意识提升计划以及医疗旅游的增长。预测期内的关键趋势包括新型放射性同位素的开发、生产和供应链创新、微流体和实验室晶片技术、放射性药物开发中的人工智慧以及奈米技术。

预计未来几年心血管疾病的盛行率不断上升将推动核医放射性同位素市场的成长。心血管疾病包括影响心臟和血管的各种疾病。这些疾病的增加归因于久坐的生活方式、不良的饮食习惯、肥胖率上升和人口老化。核医放射性同位素在心血管疾病的诊断、评估和管理中起着至关重要的作用，因为它可以提供关于心臟功能、灌注和组织活力的详细见解，而这些对于准确的诊断和有效的治疗计划至关重要。例如，2024年9月，英国心血管研究慈善机构英国心臟基金会报告称，英国约有760万人患有心臟和循环系统疾病，其中包括约400万男性和360万名女性。这些疾病约占英国所有死亡人数的 27%，每年死亡人数超过 17 万人，每天约有 480 人死亡——每三分钟就有一人死亡。因此，心血管疾病发生率的上升正在推动核医学放射性同位素市场的成长。

核医放射性同位素市场的关键参与者正致力于开发紧凑型低能量迴旋加速器等创新产品，以提高放射性同位素的产量和可用性。紧凑型低能量迴旋加速器是用于产生用于核医学成像和治疗的放射性同位素的小型粒子加速器。例如，2022 年 1 月，IBA 推出了一款新的加速器 Cyclone Key，旨在改善诊断解决方案的取得并实现放射性药物的内部生产。 Cyclone Key 具有紧凑高效的设计、全自动操作、多种同位素生产能力、易于安装和操作、水冷、自屏蔽和高性能等特点，用途广泛且可靠。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球核医放射性同位素PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球核医放射性同位素市场：成长率分析
  • 全球核医放射性同位素市场表现：规模与成长，2019-2024
  • 全球核医放射性同位素市场预测：2024-2029年及2034年规模与成长
  • 核子医学放射性同位素的全球总目标市场（TAM）

第六章市场区隔

  • 全球核医放射性同位素市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • Technetium-99m（Tc-99m）
  • 铊-201（Tl-201）
  • 碘（I-123）
  • 氟18
  • 铷-82（Rb-82）
  • 碘-131（I-131）
  • 镏-177（Lu-177）
  • 镭 223 (Ra-223) 和Alpharadin
  • 其他类型
  • 全球核医放射性同位素市场：应用、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 肿瘤学
  • 心臟病学
  • 甲状腺
  • 神经病学
  • 其他用途
  • 全球核医放射性同位素市场：依最终使用者、绩效与预测，2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 诊断中心
  • 专科诊所
  • 教育研究所
  • 其他最终用户
  • 全球核医放射性同位素市场Technetium-99m（Tc-99m）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • Technetium酸钠 Tc-99m
  • Tc-99m MDP（亚甲基二膦酸盐）
  • Tc-99m HMPAO（六甲基丙胺肟）
  • 全球核医放射性同位素市场铊-201（Tl-201）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 氯化铊 Tl-201
  • 用于心臟影像成像的铊-201
  • 全球核医放射性同位素市场碘-123（I-123）细分市场（按类型、实际及预测），2019-2024 年、2024-2029 年、2034 年
  • 碘123碘化钠
  • 碘123 碘氟烷（DaTscan）
  • 全球核医放射性同位素市场氟18细分（按类型）、绩效及预测，2019-2024年、2024-2029年、2034年
  • FDG（氟脱氧葡萄糖）F-18
  • 氟化物18用于骨骼成像
  • 全球核医放射性同位素市场铷-82（Rb-82）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 用于 PET（正子断层扫描）影像的 Rb-82
  • Rb-82心臟影像
  • 全球核医放射性同位素市场碘-131（I-131）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • I-131碘化钠
  • I-131治疗甲状腺癌
  • I-131治疗甲状腺亢进症
  • 全球核医放射性同位素市场镏-177（Lu-177）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 镥-177-多塔酸盐
  • Lu-177 在摄护腺癌治疗的应用
  • 全球核医放射性同位素市场镭-223（Ra-223）细分市场（按类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • Ra-223 二氯化物（Zofigo）
  • 全球核医放射性同位素市场Alpharadin（镭223阿尔法发射体）细分市场按类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • Alpharadin用于治疗骨转移
  • 全球核医放射性同位素市场，依型别细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • Ac-225 用于标靶阿尔法疗法 (TAT)
  • Ac-225用于癌症治疗
  • 镓-68（Ga-68）
  • 铜-64（Cu-64）
  • 钇-90（Y-90）

第七章 区域和国家分析

  • 全球核医放射性同位素市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球核医放射性同位素市场：依国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 核子医学放射性同位素市场：竞争格局
  • 核子医学放射性同位素市场：公司简介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Mallinckrodt Pharmaceuticals
  • Bracco Imaging SpA
  • Lantheus Holdings Inc.
  • Curium Pharma
  • Australian Nuclear Science and Technology Organisation（ANSTO）Health
  • Eckert & Ziegler Strahlen
  • NorthStar Medical Radioisotopes
  • NTP Radioisotopes
  • Shine Medical Technologies Inc.
  • Jubilant DraxImage Inc.
  • Isotopia Molecular Imaging Ltd.
  • EczacIbasI-Monrol Nuclear Products
  • International Isotopes Inc.
  • Polatom Sp. z oo
  • Radiomedix Inc

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年核医放射性同位素市场：提供新机会的国家
  • 2029年核医放射性同位素市场：细分领域带来新机会
  • 2029年核医放射性同位素市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r30799

Radioactive isotopes, known as nuclear medicine radioisotopes, play crucial roles in diagnosing, treating, and researching diverse medical conditions. These isotopes emit radiation that specialized equipment detects and images, aiding in diagnosis, or administer therapeutic radiation doses to specific tissues. Integral to modern medical practices, nuclear medicine radioisotopes offer essential diagnostic information and therapeutic solutions, thereby enhancing patient outcomes.

Among the primary types of nuclear medicine radioisotopes are technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), and others. Technetium-99m (Tc-99m), widely employed in nuclear medicine imaging, facilitates the diagnosis of various medical conditions across oncology, cardiology, thyroid, neurology, and other fields. End users including hospitals, diagnostic centers, specialty clinics, as well as educational and research institutes, benefit from its applications.

The nuclear medicine radioisotopes research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including the nuclear medicine radioisotopes industry's global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.21 billion in 2024 to $8.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. The rise in these diseases can be attributed to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential in diagnosing, assessing, and managing cardiovascular diseases by providing detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnoses and effective treatment planning. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 deaths annually, or approximately 480 deaths per day, which equates to one death every three minutes. As a result, the rising incidence of cardiovascular diseases is fueling the growth of the nuclear medicine radioisotope market.

Key players in the nuclear medicine radioisotopes market are concentrating on developing innovative products such as compact low-energy cyclotrons to enhance the production and availability of radioisotopes, thereby ensuring more efficient and accessible diagnostic and therapeutic options. Compact low-energy cyclotrons are small particle accelerators used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA introduced Cyclone Key, a new accelerator designed to provide increased access to diagnostic solutions and enable in-house production of radiopharmaceuticals. Cyclone Key offers features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.

In April 2024, Telix Pharmaceuticals Limited acquired ARTMS, a Canada-based company specializing in novel radioisotope technology. This acquisition aimed to bolster Telix Pharmaceuticals' nuclear medicine capabilities, optimize production procedures, and expand its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS's innovative radioisotope technology holds promise for advancing nuclear medicine applications and addressing the growing demand for radiopharmaceuticals in the diagnosis and treatment of various medical conditions, including cardiovascular diseases.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
  • 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
  • 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
  • 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
  • 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
  • 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
  • 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
  • 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
  • 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)
  • 9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment
  • 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Radioisotopes Market Characteristics

3. Nuclear Medicine Radioisotopes Market Trends And Strategies

4. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nuclear Medicine Radioisotopes Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nuclear Medicine Radioisotopes Market Growth Rate Analysis
  • 5.4. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM)

6. Nuclear Medicine Radioisotopes Market Segmentation

  • 6.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Technetium-99m (Tc-99m)
  • Thallium-201 (Tl-201)
  • Iodine (I-123)
  • Fluorine-18
  • Rubidium-82 (Rb-82)
  • Iodine-131 (I-131)
  • Lutetium-177 (Lu-177)
  • Radium-223 (Ra-223) And Alpharadin
  • Other Types
  • 6.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Thyroid
  • Neurology
  • Other Applications
  • 6.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Education And Research Institutes
  • Other End-Users
  • 6.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sodium Pertechnetate Tc-99m
  • Tc-99m MDP (Methylene Diphosphonate)
  • Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 6.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Thallous Chloride Tl-201
  • Thallium-201 for Cardiac Imaging
  • 6.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-123 Sodium Iodide
  • Iodine-123 Ioflupane (DaTscan)
  • 6.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • FDG (Fluorodeoxyglucose) F-18
  • Fluoride-18 For Bone Imaging
  • 6.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rb-82 For PET (Positron Emission Tomography) Imaging
  • Rb-82 For Cardiac Imaging
  • 6.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • I-131 Sodium Iodide
  • I-131 For Thyroid Cancer Treatment
  • I-131 For Hyperthyroidism Treatment
  • 6.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lu-177-DOTATATE
  • Lu-177 For Prostate Cancer Treatment
  • 6.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ra-223 Dichloride (Xofigo)
  • 6.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Alpharadin (Radium-223 Alpha Emitters), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpharadin For Bone Metastasis Treatment
  • 6.13. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ac-225 For Targeted Alpha Therapy (TAT)
  • Ac-225 For Cancer Treatment
  • Gallium-68 (Ga-68)
  • Copper-64 (Cu-64)
  • Yttrium-90 (Y-90)

7. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

  • 7.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Radioisotopes Market

  • 8.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Radioisotopes Market

  • 9.1. China Nuclear Medicine Radioisotopes Market Overview
  • 9.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Radioisotopes Market

  • 10.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Radioisotopes Market

  • 11.1. Japan Nuclear Medicine Radioisotopes Market Overview
  • 11.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Radioisotopes Market

  • 12.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Radioisotopes Market

  • 13.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Radioisotopes Market

  • 14.1. South Korea Nuclear Medicine Radioisotopes Market Overview
  • 14.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Radioisotopes Market

  • 15.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
  • 15.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Radioisotopes Market

  • 16.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Radioisotopes Market

  • 17.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Radioisotopes Market

  • 18.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Radioisotopes Market

  • 19.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Radioisotopes Market

  • 20.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Radioisotopes Market

  • 21.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
  • 21.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Radioisotopes Market

  • 22.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Radioisotopes Market

  • 23.1. North America Nuclear Medicine Radioisotopes Market Overview
  • 23.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Radioisotopes Market

  • 24.1. USA Nuclear Medicine Radioisotopes Market Overview
  • 24.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Radioisotopes Market

  • 25.1. Canada Nuclear Medicine Radioisotopes Market Overview
  • 25.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Radioisotopes Market

  • 26.1. South America Nuclear Medicine Radioisotopes Market Overview
  • 26.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Radioisotopes Market

  • 27.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Radioisotopes Market

  • 28.1. Middle East Nuclear Medicine Radioisotopes Market Overview
  • 28.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Radioisotopes Market

  • 29.1. Africa Nuclear Medicine Radioisotopes Market Overview
  • 29.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

  • 30.1. Nuclear Medicine Radioisotopes Market Competitive Landscape
  • 30.2. Nuclear Medicine Radioisotopes Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

  • 31.1. Mallinckrodt Pharmaceuticals
  • 31.2. Bracco Imaging S.p.A.
  • 31.3. Lantheus Holdings Inc.
  • 31.4. Curium Pharma
  • 31.5. Australian Nuclear Science and Technology Organisation (ANSTO) Health
  • 31.6. Eckert & Ziegler Strahlen
  • 31.7. NorthStar Medical Radioisotopes
  • 31.8. NTP Radioisotopes
  • 31.9. Shine Medical Technologies Inc.
  • 31.10. Jubilant DraxImage Inc.
  • 31.11. Isotopia Molecular Imaging Ltd.
  • 31.12. EczacIbasI-Monrol Nuclear Products
  • 31.13. International Isotopes Inc.
  • 31.14. Polatom Sp. z o.o.
  • 31.15. Radiomedix Inc

32. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

34. Recent Developments In The Nuclear Medicine Radioisotopes Market

35. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

  • 35.1 Nuclear Medicine Radioisotopes Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nuclear Medicine Radioisotopes Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nuclear Medicine Radioisotopes Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer